PHARMACEUTICAL IP

  • Offering
    • Evolve AI
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Biotech
    • CROs and CMOs
    • Established pharma
    • International IP counsel
    • Investors
    • Start-ups
    • Universities
  • Evolve AI
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Biotech
    • CROs and CMOs
    • Established pharma
    • International IP counsel
    • Investors
    • Start-ups
    • Universities
  • Evolve AI
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Evolve AI
  • Insights
  • Fractional IP counsel
  • Join us
  • Offering
  • Our team
  • Technologies
  • Evolve AI
  • Insights
  • Fractional IP counsel
  • Join us
  • Offering
  • Our team
  • Technologies

Our offering

Evolve is a specialist pharmaceutical and biotechnology IP firm. Our patent directors have run IP in-house, and we provide IP strategy, drafting and prosecution, freedom to operate, oppositions, due diligence and deals worldwide, with a global strategic approach.

We work with start-ups, biotech companies, established pharma, investors, universities, CROs and CMOs and international IP counsel.

  • Evolve AI
  • Fractional IP counsel
  • Technologies
Find out more

Evolve IP is able to offer commercially focused, strategic, and clear advice on complex patent portfolios

The team are thoughtful and intuitive and provide a personable service.

Evolve are friendly and knowledgeable and provide practical advice.

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

I recommend Evolve for chemical/pharma patent issues – whether prosecution or complex FTO or loss of exclusivity considerations.

Evolve Intellectual Property offers expertise in patent portfolio management, strategic planning and formalities.

Evolve Intellectual Property is a growing firm, with an excellent reputation.

Evolve is a refreshing change to the traditional patent attorney form approach – much more nimble and responsive.

Fractional IP counsel

Do you need experienced IP leadership without the overhead of a full-time in-house team? Our fractional IP counsel model places a named senior patent attorney inside your team as your head of IP. Our patent directors have run IP inside pharma and biotech companies, so they bring the real-world industry experience that you only get working in-house, backed by a specialist team and our own AI tools, with a global strategic approach.

Find out more
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Evolve AI

We are pharma patent attorneys who build and use our own AI agents. Albert for validity and competitive intelligence, Popper for global prosecution, Darwin for drafting, Cassandra for due diligence, Gilbert for quality and Franklin for invention spotting do the groundwork, so we can look at more, in more depth and earlier, while our attorneys make every judgement call.

Find out more
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

Technologies

We are technology specialists. Our team’s scientific and in-house experience spans pharmaceuticals, antibodies and other biologics, cell and gene therapies and AI drug discovery, so we understand the science behind your IP as well as the law.

Find out more
  • Pharmaceuticals
  • Biologics
  • Cell & gene therapy
  • AI drug discovery
  • All technologies

Insights

Visit Evolve Insights for our latest articles and webinars on key emerging trends and strategic considerations in pharmaceutical IP.

Read more
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly (Evolve Insights).
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert – Construe: defining your claims before they are defined for you.

  • 25th September 2026
Albert – Construe is the latest addition to Evolve’s proprietary AI toolkit.  It construes a set of claims, sets out with supporting evidence what each unclear term means, highlights any inconsistencies caused by other disclosures within an application, and flags where amendments may have changed the scope of a claim term.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Claim construction checkpoints: Application as filed versus granted patent (T 0715/24)

  • 16th September 2026
G 1/24 requires that the description must always be “consulted” to interpret a claim. The question remains whether a definition in the description can override an otherwise clear meaning in the claims. In T 0715/24, Bristol-Myers Squibb (BMS) sought to persuade the Board of Appeal that a negative feature, read together with a paragraph of…
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Evolve Intellectual Property ranked in IAM Patent 1000

  • 13th September 2026
We are proud to announce that Evolve IP has been ranked in the 2026 publication of the IAM Patent 1000: United Kingdom – England and Wales. This year’s guide highlights our deep technical expertise in life sciences and our practical, strategic business focus. Congratulations to our patent attorneys, Steven Gurney who is ranked Silver and Rose Hughes who is…

Our team

Evolve is a pharmaceutical specialist IP firm, offering comprehensive intellectual property services built on the experience of our attorneys in both in-house and private practice settings. Evolve is built on the deep expertise of our qualified attorneys in the pharmaceutical and biotech sector. With our personalized approach, scientific backgrounds and industry insights, we deliver tailored and pragmatic IP solutions for our pharmaceutical and biotechnology clients.

Meet the team

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Subscribe
  • Contact us